|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
6/13/2012 10:05:23 AM
SAN ANTONIO--(BUSINESS WIRE)--Azaya Therapeutics, Inc. announced final results from the Phase I study of its anti-cancer drug, ATI-1123 (liposomal docetaxel), today. The results showed that 79 percent of heavily pretreated patients received benefit from ATI-1123. The 29 patients enrolled in the study suffered from a variety of solid tumors, including cervical, gastric, melanoma, non-small cell lung (NSCLD), ovarian, pancreatic, prostate, thyroid, urachal and uterine cancers.
|
|
|
|
|
|
|
|
|
|
|